Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study

BACKGROUND: Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Miedema, Jelle R., Moor, Catharina C., Veltkamp, Marcel, Baart, Sara, Lie, Natascha S. L., Grutters, Jan C., Wijsenbeek, Marlies S., Mostard, Rémy L. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148498/
https://www.ncbi.nlm.nih.gov/pubmed/35643466
http://dx.doi.org/10.1186/s12931-022-02061-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148498/
https://www.ncbi.nlm.nih.gov/pubmed/35643466
http://dx.doi.org/10.1186/s12931-022-02061-2

Ejemplares similares